Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Selecta initiates phase I trial of nicotine vaccine candidate SELA-070

May 15, 2017

Embera NeuroTherapeutics' EMB-001 well tolerated in phase Ib cocaine interaction study

May 9, 2017

Cleveland BioLabs updates entolimod progress

April 18, 2017

Battelle and Nanotherapeutics form alliance on medical countermeasures

April 6, 2017

SRI International receives FDA clearance to evaluate novel oral formulation of Zn-DTPA

April 3, 2017

BARDA elects not to exercise options for AEOL-10150 development for ARS and DEARE

March 28, 2017

Opiant receives FDA feedback on development of OPNT-002 for alcohol use disorder

March 2, 2017

Aeolus Pharmaceuticals starts phase I study of new formulation of AEOL-10150

Feb. 23, 2017

FDA issues complete response letter for Amphastar's intranasal naloxone

Feb. 23, 2017

Adapt Pharma applies for E.U. approval of naloxone HCl nasal spray

Feb. 22, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal
BioWorld
The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as...